IBRX vs. LNTH, BBIO, BPMC, LEGN, ELAN, CYTK, NUVL, GRFS, KRYS, and TGTX
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Lantheus (LNTH), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Krystal Biotech (KRYS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
ImmunityBio vs.
ImmunityBio (NASDAQ:IBRX) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
Lantheus received 331 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 65.89% of users gave Lantheus an outperform vote while only 30.00% of users gave ImmunityBio an outperform vote.
In the previous week, ImmunityBio had 2 more articles in the media than Lantheus. MarketBeat recorded 19 mentions for ImmunityBio and 17 mentions for Lantheus. Lantheus' average media sentiment score of 0.56 beat ImmunityBio's score of 0.40 indicating that Lantheus is being referred to more favorably in the news media.
8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ImmunityBio has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
ImmunityBio currently has a consensus target price of $13.58, suggesting a potential upside of 362.02%. Lantheus has a consensus target price of $131.86, suggesting a potential upside of 44.15%. Given ImmunityBio's higher possible upside, equities research analysts clearly believe ImmunityBio is more favorable than Lantheus.
Lantheus has a net margin of 28.57% compared to ImmunityBio's net margin of -8,016.83%. Lantheus' return on equity of 44.29% beat ImmunityBio's return on equity.
Lantheus has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Summary
Lantheus beats ImmunityBio on 12 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
This page (NASDAQ:IBRX) was last updated on 1/21/2025 by MarketBeat.com Staff
